Agilent Introduces the Cary 635 FTIR Spectrometer
SANTA CLARA, Calif., September 01, 2026--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the Agilent Cary 635 FTIR spectrometer, setting a new standard for compact, high-performance Fourier transform infrared (FTIR) analysis. Combining robust engineering, superior performance, and intuitive usability, the Cary 635 FTIR provides laboratories with a powerful solution that enhances reliability, boosts productivity, and delivers the versatility required for today’s analytical chal
Yahoo3 days agoA
Agilent (A) Q3 2026 Earnings Call Transcript
Pharma revenue surged 12% while advanced therapeutics grew nearly 30%, beating guidance.
Yahoo4 days agoA
International Markets and Agilent (A): A Deep Dive for Investors
Explore how Agilent's (A) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Yahoo4 days agoA
Laboratory Modernization Strengthens QPS Holdings, LLC’s Long-Term Commitment to Elemental Bioanalysis
GRONINGEN, Netherlands, August 31, 2026--QPS announces a significant renewal of its elemental bioanalysis infrastructure through the acquisition of two PerkinElmer NexION® 2200 machines.
Yahoo4 days agoA
Agilent (NYSE) Expanded Non-GAAP Margin 320 bps. How Much Is Repeatable?
Agilent Technologies, Inc. (NYSE:A) delivered fiscal third-quarter revenue of $1.88 billion, an increase of 8.1% from a year earlier. Core revenue, which excludes currency movements and recent acquisitions and divestitures, grew 7.3%. The company-defined non-GAAP operating margin of Agilent Technologies, Inc. (NYSE:A) reached 28.3%, expanding 320 basis points year over year. Approximately 110 basis points […]
Yahoo6 days agoA
A Q2 Deep Dive: Product Momentum, China Recovery, and Operating Leverage Drive Results
Life sciences tools company Agilent Technologies (NYSE:A) announced better-than-expected revenue in Q2 CY2026, with sales up 8.1% year on year to $1.88 billion. Guidance for next quarter’s revenue was better than expected at $1.99 billion at the midpoint, 1% above analysts’ estimates. Its non-GAAP profit of $1.62 per share was 9% above analysts’ consensus estimates.
Yahoo7 days agoA
Agilent Technologies (A) Has Investors Looking Closer After Its Latest Update
Agilent Technologies (A) is back in focus after raising its fiscal 2026 revenue guidance to a range of $7.49b to $7.51b, alongside fresh fourth quarter projections tied to its latest earnings release. The raised 2026 guidance and stronger recent quarters have come alongside a clear shift in how the market is pricing Agilent Technologies, with a 30 day share price return of 12.20% and a 1 year total shareholder return of 27.21%, which points to building momentum rather than fading...
Yahoo7 days agoA
Lithium Miners News For The Month Of August 2026
Lithium prices rebound as CATL shutdown risks a deficit; miners post strong H1 results, and new supply deals form. Read the full news roundup here.
SeekingAlpha9 days agoA
Broadcom: Moving Big Into Vendor Financing
Broadcom Inc.: AI chip growth targets, SPV financing and default risks, insider selling, and valuationâsee why investors may avoid now. Click for more on AVGO stock.
SeekingAlpha9 days agoA
Exploring Analyst Estimates for Agilent (A) Q3 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Agilent (A), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended July 2026.
Yahoo14 days agoA
What Are Wall Street Analysts' Target Price for Agilent Technologies Stock?
Despite Agilent Technologies’ strong performance relative to the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
Yahoo14 days agoA
MDT vs. A: Which Stock Should Value Investors Buy Now?
MDT vs. A: Which Stock Is the Better Value Option?
Yahoo17 days agoA
Cannabis Testing Services Market Research Report 2026-2031: Profiles Agilent, Eurofins, SGS, and 18 Other Companies
Dublin, Aug. 18, 2026 (GLOBE NEWSWIRE) -- The "Cannabis Testing Services - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. The global cannabis testing services market was valued at USD 359.68 million in 2025 and is expected to increase from USD 397.85 million in 2026 to USD 688.46 million by 2031. The market is projected to register a compound annual growth rate of 11.59% during the 2026-2031 forecast period.
Yahoo17 days agoA
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.
Yahoo17 days agoA
Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside
SeekingAlpha19 days agoA
Danaher: 2027 Growth Reacceleration Should Drive Upside
SeekingAlpha21 days agoA
Morgan Stanley Maintains Overweight on Agilent Technologies, Raises Price Target to $175
Morgan Stanley analyst Kallum Titchmarsh maintains Agilent Technologies (NYSE:A) with a Overweight and raises the price target from $160 to $175.
Benzinga23 days agoA
Agilent Technologies (A) Secures Expanded EU Approval For Ovarian Cancer Test
Agilent Technologies (NYSE:A) secured expanded European approval for its PD-L1 IHC 22C3 pharmDx test for ovarian cancer applications. The CE-marked indication now covers patients with ovarian, fallopian tube, and primary peritoneal carcinoma in the EU. The move strengthens Agilent's oncology diagnostics portfolio and supports wider use of targeted cancer therapies in Europe. For readers looking to explore more stocks tied to the rise of data driven tools in cancer care and diagnostics, a...
Yahoo28 days agoA
BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates
BioLife Solutions (BLFS) delivered earnings and revenue surprises of +500.00% and +1.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo28 days agoA
[Latest] Global gRNA Market Size/Share Worth USD 2950 Million by 2034 at a 19% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global gRNA Market size & share revenue was valued at approximately USD 518 Million in 2024 and is expected to reach USD 616 Million in 2025 and is expected to reach around USD 2950 Million by 2034, at a CAGR of 19% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scientific Inc., Agilent Technolo
Yahoo28 days agoA
Navigating Alphabet’s (GOOGL) AI Frontier
Bronte Capital, an investment management company, released its “Amalthea Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Fund posted a 6.49% net return in June, bringing the quarterly returns to 5.12%, compared to 3.17% and 14.48% for the globally diverse MSCI ACWI in ($A), respectively. The outperformance in June […]
Yahoo29 days agoA
Envista (NVST) Q2 Earnings and Revenues Surpass Estimates
Envista (NVST) delivered earnings and revenue surprises of +24.24% and +2.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo29 days agoA
Are Options Traders Betting on a Big Move in Agilent Technologies Stock?
Investors need to pay close attention to A stock based on the movements in the options market lately.
Yahoolast monthA
If You Invested $1000 in Keysight a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Yahoolast monthA